Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study.
- Conditions
- HyperfibrinogenemiaHemostatic Disorder
- Registration Number
- NCT06571552
- Lead Sponsor
- Centre Hospitalier Universitaire de Nimes
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria:<br><br> - Patients without renal failure treated with chronic therapeutic plasmapheresis with<br> a minimum treatment interval of 10 days and who can be treated with single plasma<br> exchange (SPE) or double filtration plasmapheresis (DFPP) in accordance with the<br> international recommendations.<br><br> - Therapeutic plasmapheresis with regional citrate anticoagulation.<br><br> - Patients over 18 years of age.<br><br> - Patient affiliated to or benefiting from a social security scheme.<br><br> - Free, informed and written consent, signed by the participant and the investigator<br> (at the latest on the day of inclusion and before any examination required by the<br> research).<br><br>Exclusion Criteria:<br><br> - Patients treated with oral anticoagulants or anti-platelet agents.<br><br> - Patients treated for hypercholesterolaemia or hypertriglyceridaemia; hyperviscosity,<br> acquired haemophilia or nephrotic syndrome.<br><br> - Indication for substitution with fresh frozen plasma (FFP) for the treatment of the<br> disease.<br><br> - Patient in an exclusion period determined by another study.<br><br> - Patient under court protection, guardianship or curatorship.<br><br> - Patient unable to give consent.<br><br> - Patient for whom it is impossible to give informed information.<br><br> - Pregnant or breast-feeding patients.
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method